The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators--A pilot study

Clinical Biochemistry
Marek KuceraLudovit Gaspar

Abstract

The mean platelet volume (MPV) and red cell distribution width (RDW) have recently arisen interest because of their association with an increased cardiovascular risk. The aim of our study was, therefore, to determine whether an association exists between MPV, RDW and lipoprotein sub-fractions, and to show the impact of statin therapy on these new possible biomarkers of atherosclerotic risk. A cohort of 40 patients with hypercholesterolaemia (29 females, mean age 62.9±9 years), without previous hypolipidaemic treatment were enrolled. The patients were treated with atorvastatin 40 mg/day for 12 weeks. Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density cholesterol (HDL-C), triglycerides (TG), LDL-C sub-fractions [large LDL-C 1-2 and small dense (sd)-LDL-C 3-7], apolipoproteins (apoA1, apoB), apoB/apoA1 ratio, atherogenic index of plasma (AIP), haematological parameters (including MPV, RDW) and safety parameters (renal, hepatic) were measured before and after 12 weeks of atorvastatin treatment. At baseline, a strong correlation between HDL-C, TG, sd-LDL-C, apoB, apoB/apoA1, and AIP with MPV (r=-0.55, p<0.001; r=0.57, p<0.001; r=0.73, p<0.001; r=0.41, p<0.05; r=0.52, p<0.001; r=0.61, p<0.001, respectiv...Continue Reading

References

Jan 1, 1991·The Journal of Emergency Medicine·T C Evans, D Jehle
Jan 12, 2002·International Journal of Cardiology·Christoph BickelUNKNOWN AtheroGene Group
Dec 20, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·V GaddamJ L Mehta
Jan 16, 2007·The American Journal of Cardiology·Jeffrey L AndersonUNKNOWN Intermountain Heart Collaborative (IHC) Study Group
Dec 14, 2007·The New England Journal of Medicine·Giovanni Davì, Carlo Patrono
Jan 4, 2008·Circulation·Marcello TonelliUNKNOWN for the Cholesterol and Recurrent Events (CARE) Trial Investigators
Apr 12, 2008·The New England Journal of Medicine·John R Kapoor
May 22, 2008·Atherosclerosis·Tetsuo ShojiYoshiki Nishizawa
Mar 25, 2009·Archives of Internal Medicine·Todd S PerlsteinJoshua A Beckman
Feb 6, 2010·Current Medical Research and Opinion·Vasilios G AthyrosDimitri P Mikhailidis
Mar 14, 2012·European Journal of Clinical Investigation·Boguslawa LuzakCezary Watala
May 23, 2012·Circulation·Pasquale PignatelliFrancesco Violi
Feb 15, 2014·World Journal of Cardiology·Olli Arjamaa

❮ Previous
Next ❯

Citations

Nov 26, 2015·Clinical Biochemistry·Peter A KavsakCatherine A Hammett-Stabler
Apr 21, 2017·Current Opinion in Cardiology·Philipp A GerberManfredi Rizzo
Jun 19, 2015·Angiology·N Papanas, E Maltezos
Mar 22, 2018·Nature Reviews. Rheumatology·Petrus LingeEric Boilard
May 19, 2016·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·Y-F PengY-S Wei
Mar 1, 2017·Current Atherosclerosis Reports·Mario da Silva Garrote-FilhoNilson Penha-Silva

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.